Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 7, 2015, Pages H1130-H1140

  Wang, Hongfeng ^a   Weihrauch, Dorothee ^b   Kersten, Judy R ^b   Toth, Jeffrey M ^a,b   Passerini, Anthony G ^c   Rajamani, Anita ^c   Schrepfer, Sonja ^d,e   LaDisa, John F ^a,b  

^a Medical College of Wisconsin and Marquette University   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c University of California   (United States)

^d UNIVERSITY HEART CENTER HAMBURG   (Germany)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Hemodynamics; Hyperglycemia; Interventional cardiology; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; CEFAZOLIN; GLUCOSE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; POLYVINYLIDENE FLUORIDE; TRANSFORMING GROWTH FACTOR BETA; AGER PROTEIN, RAT; COLLAGEN; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; FLOW RATE; GLUCOSE BLOOD LEVEL; HYPERPLASIA; MALE; NEOINTIMA; NEOINTIMAL HYPERPLASIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHEAR STRESS; SIGNAL TRANSDUCTION; STENT; VASCULAR RESISTANCE; ABDOMINAL AORTA; ANIMAL; DIABETES MELLITUS; DRUG EFFECTS; GRAFT OCCLUSION; MECHANICAL STRESS; METABOLISM; SHEAR STRENGTH; ZUCKER RAT;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; AORTA, ABDOMINAL; COLLAGEN; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; GRAFT OCCLUSION, VASCULAR; MALE; NEOINTIMA; OBESITY; RATS; RATS, ZUCKER; SHEAR STRENGTH; STENTS; STRESS, MECHANICAL; THIAZOLES; TRANSFORMING GROWTH FACTOR BETA; VASCULAR RESISTANCE;

EID: 84943144084     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00123.2014     Document Type: Article

References (55)

1. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, Williams C, Torres RL, Wagle D, Ulrich P, Cerami A, Brines M, Regan TJ. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 97: 2809-2813, 2000.
2. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 17: 23S-30S, 2004.
3. Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes. II: Recent advances in coronary revascularization. J Am Coll Cardiol 49: 643-656, 2007.
4. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
5. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46: 223-234, 1995.
6. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92: 785-792, 2003.
7. Center for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States. Atlanta, GA: National Center for Chronic Disease Prevention and Health Promotion, 2011.
8. Cooper ME. Importance of advanced glycation end products in diabetesassociated cardiovascular and renal disease. Am J Hypertens 17: 31S-38S, 2004.
9. Cortizo AM, Lettieri MG, Barrio DA, Mercer N, Etcheverry SB, McCarthy AD. Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem 250: 1-10, 2003.
10. Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl 106: S54-S60, 2007.
11. De la Torre Hernandez JM, Alfonso F, Sanchez Recalde A, Jimenez Navarro MF, Perez de Prado A, Hernandez F, Abdul-Jawad Altisent O, Roura G, Garcia Camarero T, Elizaga J, Rivero F, Gimeno F, Calviño R, Moreu J, Bosa F, Rumoroso JR, Bullones JA, Gallardo A, Fernandez Diaz JA, Ruiz Arroyo JR, Aragon V, Masotti M; ESTROFA-LM Study Group. Comparison of paclitaxel-eluting stents (Taxus) and everolimus-eluting stents (Xience) in left main coronary artery disease with 3 years follow-up (from the ESTROFA-LM registry). Am J Cardiol 111: 676-683, 2013.
12. Deuse T, Ikeno F, Robbins RC, Schrepfer S. Imaging in-stent restenosis: an inexpensive, reliable, and rapid preclinical model. J Vis Exp 14: 1346, 2009.
13. DeVerse JS, Bailey KA, Jackson KN, Passerini AG. Shear stress modulates RAGE-mediated inflammation in a model of diabetes-induced metabolic stress. Am J Physiol Heart Circ Physiol 302: H2498-H2508, 2012.
14. DeVerse JS, Sandhu AS, Mendoza N, Edwards CM, Sun C, Simon SI, Passerini AG. Shear stress modulates VCAM-1 expression in response to TNF-α and dietary lipids via interferon regulatory factor-1 in cultured endothelium. Am J Physiol Heart Circ Physiol 305: H1149-H1157, 2013.
15. Dudek D, Legutko J, Heba G, Bartus S, Partyka L, Huk I, Dembinska-Kiec A, Kaluza GL, Dubiel JS. L-Arginine supplementation does not inhibit neointimal formation after coronary stenting in human beings: an intravascular ultrasound study. Am Heart J 147: E12, 2004.
16. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53: 1813-1823, 2004.
17. Garasic JM, Edelman ER, Squire JC, Seifert P, Williams MS, Rogers C. Stent and artery geometry determine intimal thickening independent of arterial injury. Circulation 101: 812-818, 2000.
18. Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 27: 990-994, 2004.
19. Goldfine AB, Beckman JA. Life and death in Denmark: lessons about diabetes and coronary heart disease. Circulation 117: 1914-1917, 2008.
20. Hakim DA, Mintz GS, Sanidas E, Rusinova R, Weisz G, Leon MB, Moses JW, Stone GW, Maehara A. Serial gray scale intravascular ultrasound findings in late drug-eluting stent restenosis. Am J Cardiol 111: 695-699, 2013.
21. Hinagata J, Kakutani M, Fujii T, Naruko T, Inoue N, Fujita Y, Mehta JL, Ueda M, Sawamura T. Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model. Cardiovasc Res 69: 263-271, 2006.
22. Hioki H, Kumazaki S, Izawa A. Critical in-stent restenosis following fracture of biolimus-eluting stent: a report of 2 cases. J Invasive Cardiol 25: E11-E13, 2013.
23. Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, Esposito G, Carriero MV, Rapacciuolo A, Di Lorenzo E, Stabile E, Perrino C, Chieffo A, Pardo F, Chiariello M. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation 103: 2980-2986, 2001.
24. Jonas M, Edelman ER, Groothuis A, Baker AB, Seifert P, Rogers C. Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin-resistant and diabetic animals. Circ Res 97: 725-733, 2005.
25. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, de-Groof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104: 1464-1470, 2001.
26. Khan W, Farah S, Domb AJ. Drug eluting stents: developments and current status. J Control Release 161: 703-712, 2012.
27. Kutryk MJ, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, deFeyter PJ, Bruining N, Sabate M, Serruys PW. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 39: 281-287, 2002.
28. LaDisa JF Jr, Olson LE, Hettrick DA, Warltier DC, Kersten JR, Pagel PS. Axial stent strut angle influences wall shear stress after stent implantation: analysis using 3D computational fluid dynamics models of stent foreshortening. Biomed Eng Online 4: 59, 2005.
29. LaDisa JF Jr, Olson LE, Molthen RC, Hettrick DA, Pratt PF, Hardel MD, Kersten JR, Warltier DC, Pagel PS. Alterations in wall shear stress predict sites of neointimal hyperplasia after stent implantation in rabbit iliac arteries. Am J Physiol Heart Circ Physiol 288: H2465-H2475, 2005.
30. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 7: 29, 2008.
31. Morrison TM, Choi G, Zarins CK, Taylor CA. Circumferential and longitudinal cyclic strain of the human thoracic aorta: age-related changes. J Vasc Surg 49: 1029-1036, 2009.
32. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315-1323, 2003.
33. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 90: 10759-10763, 1993.
34. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest 90: 1582-1592, 1992.
35. Noh H, King GL. The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl S49-S53, 2007.
36. Oyamada S, Ma X, Wu T, Robich MP, Wu H, Wang X, Buchholz B, McCarthy S, Bianchi CF, Sellke FW, Laham R. Trans-iliac rat aorta stenting: a novel high throughput preclinical stent model for restenosis and thrombosis. J Surg Res 166: e91-e95, 2011.
37. Park SH, Marso SP, Zhou Z, Foroudi F, Topol EJ, Lincoff AM. Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 104: 815-819, 2001.
38. Peppa M, Uribarri J, Vlassara H. The role of advanced glycation end products in the development of atherosclerosis. Curr Diab Rep 4: 31-36, 2004.
39. Peppa M, Vlassara H. Advanced glycation end products and diabetic complications: a general overview. Hormones (Athens) 4: 28-37, 2005.
40. Ryan J, Cohen DJ. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation 114: 1736-1743, 2006.
41. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498: 99-111, 2000.
42. Srikrishna G, Huttunen HJ, Johansson L, Weigle B, Yamaguchi Y, Rauvala H, Freeze HH. N-glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J Neurochem 80: 998-1008, 2002.
43. Stefek M, Gajdosik A, Gajdosikova A, Krizanova L. p-Dimethylaminobenzaldehyde-reactive substances in tail tendon collagen of streptozotocin-diabetic rats: temporal relation to biomechanical properties and advanced glycation endproduct (AGE)-related fluorescence. Biochim Biophys Acta 1502: 398-404, 2000.
44. Stone GW, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, Smits PC. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 124: 893-900, 2011.
45. Taşkiran DT, Taşkiran E, Yercan H, Kutay FZ. Quantification total collagen in rabbit tendon by the Sirius red. Tr J Med Sci 29: 7-9, 1999.
46. Tsou JK, Gower RM, Ting HJ, Schaff UY, Insana MF, Passerini AG, Simon SI. Spatial regulation of inflammation by human aortic endothelial cells in a linear gradient of shear stress. Microcirculation 15: 311-323, 2008.
47. Vasan S, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382: 275-278, 1996.
48. Vladic N, Ge ZD, Leucker T, Brzezinska AK, Du JH, Shi Y, Warltier DC, Pratt PF Jr, Kersten JR. Decreased tetrahydrobiopterin and disrupted association of Hsp90 with eNOS by hyperglycemia impair myocardial ischemic preconditioning. Am J Physiol Heart Circ Physiol 301: H2130-H2139, 2011.
49. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 251: 87-101, 2002.
50. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A. Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol 22: 940-948, 2002.
51. Watson AM, Gray SP, Jiaze L, Soro-Paavonen A, Wong B, Cooper ME, Bierhaus A, Pickering R, Tikellis C, Tsorotes D, Thomas MC, Jandeleit-Dahm KA. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes 61: 2105-2113, 2012.
52. Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D'Agati V, Schmidt AM. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14: 1383-1395, 2003.
53. Windberger U, Bartholovitsch A, Plasenzotti R, Korak KJ, Heinze G. Whole blood viscosity, plasma viscosity and erythrocyte aggregation in nine mammalian species: reference values and comparison of data. Exp Physiol 88: 431-440, 2003.
54. Yao EH, Fukuda N, Ueno T, Matsuda H, Matsumoto K, Nagase H, Matsumoto Y, Takasaka A, Serie K, Sugiyama H, Sawamura T. Novel gene silencer pyrrole-imidazole polyamide targeting lectin-like oxidized low-density lipoprotein receptor-1 attenuates restenosis of the artery after injury. Hypertension 52: 86-92, 2008.
55. Yazdani SK, Nakano M, Otsuka F, Kolodgie FD, Virmani R. Atheroma and coronary bifurcations: before and after stenting. EuroIntervention 6, Suppl J: J24-J30, 2010.